Back to results

Imaging Lung Function Using Oxygen Enhanced MRI

Primary Purpose

COPD, Asthma, Cystic Fibrosis

Status

Completed

Phase

Phase 1

Locations

United States

Study Type

Interventional

Intervention

Medical Grade Oxygen

About this trial

This is an interventional diagnostic trial for COPD

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria for Lung and/or Airway Disease

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
1. Subjects must be ≥ 18 years of age;
2. Evidence of lung disease or injury by medical history, physical exam, and/or clinical laboratories;
  - COPD
  - Asthma
  - Pre/Post Lung Transplant
  - Cystic Fibrosis
  - Emphysema/Other Small Airways Diseases
  - Lung Transplant
3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
4. Subjects who are willing and able to comply with scheduled visits and other trial procedures.

Exclusion Criteria for Subjects with Lung and/or Airway Disease:

Subjects presenting with any of the following will not be included in the trial:

Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications (e.g. metal in the eye, claustrophobia);
Unable to receive 100% oxygen by breathing because of potential hypercapnia ( SpO2 <90% or FEV1 < 1 L);
Participation in a clinical trial with a study drug that may impact lung function in the past 14 days; or
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial. This determination is made by the referring physician based on standard clinical practice.
Female; women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MR scan, prior to the MRI scan.

Inclusion Criteria for Normal Subjects Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:

Subjects must be ≥ 18 years of age;
Non-smokers, ex-smokers with normal pulmonary function test by spirometry;
No Evidence of prior lung disease or lung injury by medical history, physical exam, and/or clinical laboratories;
Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
Subjects who are willing and able to comply with scheduled visits and other trial procedures.

Exclusion Criteria for Normal Subjects

Subjects presenting with any of the following will not be included in the trial:

Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications (e.g. metal in the eye, claustrophobia);
Unable to receive 100% oxygen by breathing because of potential hypercapnia (SpO2 <90% or FEV1 < 1 L) (Note, we consider this highly unlikely in a 'normal' subject);
Participation in a clinical trial with a study drug that may impact lung function in the past 14 days; or
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
Female; women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MR scan, prior to the MRI scan.

Sites / Locations

Duke University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Arm Label

Normal Subject

Subjects with Lung/or Airway Disease

Arm Description

Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.

Outcomes

Primary Outcome Measures

Image Quality

Assessment of image quality of oxygen enhanced MR images: Signal to Noise Ratio, Dynamic Range of Ratio/Difference Images

Secondary Outcome Measures

Full Information

NCT ID

NCT01731015

First Posted

November 16, 2012

Last Updated

August 20, 2014

Sponsor

Hal C Charles

1. Study Identification

Unique Protocol Identification Number

NCT01731015

Brief Title

Imaging Lung Function Using Oxygen Enhanced MRI

Official Title

A Pilot Study for Evaluation of Regional Lung Function in Normal Subjects and Subjects With Airway and Lung Disorders Using 1H Magnetic Resonance Imaging With Oxygen as a Contrast Agent

Study Type

Interventional

2. Study Status

Record Verification Date

November 2012

Overall Recruitment Status

Completed

Study Start Date

January 2012 (undefined)

Primary Completion Date

September 2012 (Actual)

Study Completion Date

September 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor-Investigator

Name of the Sponsor

Hal C Charles

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

The goal of this study is to perform a pilot study to evaluate the utilization of oxygen as an inhaled contrast agent to image the airway spaces in normal and diseased human lungs to allow an effect size estimate to power future studies.

Detailed Description

This is an open label study expanding on work by other groups in animals, ex-vivo human lungs and human subjects. Both 2-dimensional and 3-dimensional images will be obtained using 1H MRI comparing images obtained while breathing oxygen to those obtained breathing room air. Objectives To determine if 1H magnetic resonance images of the human lung and airways can be obtained in both single breath-hold and gated breathing imaging studies with adequate signal level and image contrast to extract regional lung functional information with oxygen as a contrast agent. To determine the short term reproducibility of the lung functional imaging in a subset of subjects (5 control subjects and 5 subjects with lung disease) with repeat MRI studies (Visit 2) at a time point ≥ 1 week to ≤ 4 weeks from Visit 1

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Disease

7. Study Design

Primary Purpose

Diagnostic

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

15 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Normal Subject

Arm Type

Experimental

Arm Description

Arm Title

Subjects with Lung/or Airway Disease

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

Medical Grade Oxygen

Other Intervention Name(s)

oxygen

Intervention Description

At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience ~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.

Primary Outcome Measure Information:

Title

Image Quality

Description

Assessment of image quality of oxygen enhanced MR images: Signal to Noise Ratio, Dynamic Range of Ratio/Difference Images

Time Frame

one exposure

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

90 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria for Lung and/or Airway Disease Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial: Subjects must be ≥ 18 years of age; Evidence of lung disease or injury by medical history, physical exam, and/or clinical laboratories; COPD Asthma Pre/Post Lung Transplant Cystic Fibrosis Emphysema/Other Small Airways Diseases Lung Transplant Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial. Subjects who are willing and able to comply with scheduled visits and other trial procedures. Exclusion Criteria for Subjects with Lung and/or Airway Disease: Subjects presenting with any of the following will not be included in the trial: Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications (e.g. metal in the eye, claustrophobia); Unable to receive 100% oxygen by breathing because of potential hypercapnia ( SpO2 <90% or FEV1 < 1 L); Participation in a clinical trial with a study drug that may impact lung function in the past 14 days; or Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial. This determination is made by the referring physician based on standard clinical practice. Female; women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MR scan, prior to the MRI scan. Inclusion Criteria for Normal Subjects Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial: Subjects must be ≥ 18 years of age; Non-smokers, ex-smokers with normal pulmonary function test by spirometry; No Evidence of prior lung disease or lung injury by medical history, physical exam, and/or clinical laboratories; Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial. Subjects who are willing and able to comply with scheduled visits and other trial procedures. Exclusion Criteria for Normal Subjects Subjects presenting with any of the following will not be included in the trial: Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications (e.g. metal in the eye, claustrophobia); Unable to receive 100% oxygen by breathing because of potential hypercapnia (SpO2 <90% or FEV1 < 1 L) (Note, we consider this highly unlikely in a 'normal' subject); Participation in a clinical trial with a study drug that may impact lung function in the past 14 days; or Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial. Female; women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MR scan, prior to the MRI scan.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Cecil Charles, PhD

Organizational Affiliation

Duke University

Official's Role

Principal Investigator

Facility Information:

Facility Name

Duke University Medical Center

City

Durham

State/Province

North Carolina

ZIP/Postal Code

27705

Country

United States

12. IPD Sharing Statement

Learn more about this trial

Imaging Lung Function Using Oxygen Enhanced MRI

We'll reach out to this number within 24 hrs